Decreased microglial Wnt/β-catenin signalling drives microglial pro-inflammatory activation in the developing brain

Juliette Van Steenwinckel1,2, Anne-Laure Schang1,2,3, Michelle L Krishnan4

  • 1Université de Paris, NeuroDiderot, Inserm, F-75019 Paris, France.

Insights

Reduced Wnt/β-catenin signaling in the developing brain drives microglial activation, leading to hypomyelination and neurological issues in preterm infants. Targeting this pathway offers a potential therapeutic strategy for brain injury.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Immunology

Background:

  • Microglia, the brain's immune cells, have unique developmental functions, but their activation regulation is unclear.
  • Neuroinflammation in preterm infants' developing brains is linked to permanent neurological damage in millions annually.
  • Understanding microglial activation is crucial for addressing neonatal brain injury.

Purpose of the Study:

  • To investigate regulators of microglial activation in the developing brain.
  • To determine the role of Wnt/β-catenin signaling in neuroinflammation-mediated injury.
  • To explore Wnt pathway as a therapeutic target for neonatal brain injury.

Main Methods:

  • Analysis of genes and proteins in mouse, zebrafish, and primary human/mouse microglia models.
  • Genomic variation analysis in a cohort of preterm infants.
  • In vivo studies using Wnt agonist delivered via microglia-specific nanocarriers.

Main Results:

  • Reduced Wnt/β-catenin signaling drives a microglial phenotype causing hypomyelination.
  • Genomic variations in the Wnt pathway correlate with brain connectivity in preterm infants.
  • Wnt agonist therapy prevented pro-inflammatory microglial activation, white matter injury, and behavioral deficits in animal models.

Conclusions:

  • The Wnt pathway is a key regulator of microglial activation in the developing brain.
  • Wnt pathway dysregulation is critical in the pathogenesis of a significant form of human brain injury.
  • Targeting the Wnt pathway presents a viable therapeutic strategy for neonatal brain injury.